Theranostic tumor homing nanocarriers for the treatment of lung cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 5, 2014, Pages e1053-e1063

  Patel, Apurva R ^a   Chougule, Mahavir B ^b   Lim, Ed ^c   Francis, Kevin P ^c   Safe, Stephen ^d   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

^c PERKINELMER INC   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer treatment; In vivo imaging; Nanoparticles; Targeted delivery; Theranostic; Tumor homing

Indexed keywords

BIOLOGICAL ORGANS; BLOOD; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; NANOPARTICLES; ONCOLOGY; PEPTIDES; TUMORS;

CANCER THERAPEUTICS; DELIVERY SYSTEMS; IN-VIVO IMAGING; LUNG CANCER DIAGNOSIS; TARGETED DELIVERY; TARGETED EFFICIENCY; THERANOSTIC; TUMOR VASCULATURE;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CREKA PEPTIDE NANOPARTICLE; DIM C PPHC6H5; MATRIGEL; NANOPARTICLE; UNCLASSIFIED DRUG; VASCULOTROPIN; CYSTEINYL-ARGINYL-GLUTAMYL-LYSYL-ALANYL; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; FLUORESCENCE IMAGING; FREEZE DRYING; LUNG CANCER; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; NUDE MOUSE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NANOPARTICLES; OLIGOPEPTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903527626     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.12.002     Document Type: Article

References (50)

1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(5):584-594.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. Target Oncol 2013, 8(1):15-26.
3. Schmid-Bindert G. Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC). Target Oncol 2013.
4. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A., Tung M.Y., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001, 8(1):72-79.
5. Fontanini G., Faviana P., Lucchi M., Boldrini L., Mussi A., Camacci T., et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002, 86(4):558-563.
6. Gasparini G., Longo R., Fanelli M., Teicher B.A. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005, 23(6):1295-1311.
7. Ichite N., Chougule M.B., Jackson T., Fulzele S.V., Safe S., Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res 2009, 15(2):543-552.
8. Ichite N., Chougule M., Patel A.R., Jackson T., Safe S., Singh M. Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Mol Cancer Ther 2010, 9(11):3003-3014.
9. Patel A.R., Spencer S.D., Chougule M.B., Safe S., Singh M. Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM). Eur J Pharm Sci 2012, 46(1-2):8-16.
10. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1):16-20.
11. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14(5):1310-1316.
12. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006, 5(8):1909-1917.
13. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60(15):1615-1626.
14. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66(13):6732-6740.
15. Iinuma H., Maruyama K., Okinaga K., Sasaki K., Sekine T., Ishida O., et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002, 99(1):130-137.
16. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007, 59(6):491-504.
17. Souto E.B., Wissing S.A., Barbosa C.M., Muller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004, 278(1):71-77.
18. Pardeike J., Hommoss A., Muller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009, 366(1-2):170-184.
19. Muller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002, 54(Suppl. 1):S131-S155.
20. Selvamuthukumar S., Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis 2012, 11:159.
21. van Vlerken L.E., Amiji M.M. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006, 3(2):205-216.
22. Muthu M.S., Kulkarni S.A., Raju A., Feng S.S. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 2012, 33(12):3494-3501.
23. Wu W., Shen J., Gai Z., Hong K., Banerjee P., Zhou S. Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery. Biomaterials 2011, 32(36):9876-9887.
24. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A 2007, 104(3):932-936.
25. Dvorak H.F., Senger D.R., Dvorak A.M., Harvey V.S., McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985, 227(4690):1059-1061.
26. Agemy L., Sugahara K.N., Kotamraju V.R., Gujraty K., Girard O.M., Kono Y., et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 2010, 116(15):2847-2856.
27. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5(1):73-82.
28. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6(4):715-728.
29. Stefanick J.F., Ashley J.D., Kiziltepe T., Bilgicer B. A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. ACS Nano 2013, 7(4):2935-2947.
30. Patel A.R., Chougule M.B., I T., Patlolla R., Wang G., Singh M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res 2013, 30(5):1435-1446.
31. Singh A., Ahmad I., Akhter S., Jain G.K., Iqbal Z., Talegaonkar S., et al. Nanocarrier based formulation of thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies. Colloids Surf B Biointerfaces 2013, 102:822-832.
32. Chikh G.G., Li W.M., Schutze-Redelmeier M.P., Meunier J.C., Bally M.B. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 2002, 1567(1-2):204-212.
33. Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996, 275(3):150-154.
34. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007, 13(7):1961-1970.
35. Kumar S., Li C. Targeting of vasculature in cancer and other angiogenic diseases. Trends Immunol 2001, 22(3):129.
36. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005, 333(2):328-335.
37. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53(2):283-318.
38. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31(6):1360-1371.
39. Lim S.M., Kim T.H., Jiang H.H., Park C.W., Lee S., Chen X., et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 2011, 32(13):3538-3546.
40. Fang Y.P., Wu P.C., Huang Y.B., Tzeng C.C., Chen Y.L., Hung Y.H., et al. Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. Int J Nanomedicine 2012, 7:4995-5005.
41. Chintharlapalli S., Papineni S., Safe S. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways. Mol Pharmacol 2007, 71(2):558-569.
42. Chintharlapalli S., Papineni S., Baek S.J., Liu S., Safe S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 2005, 68(6):1782-1792.
43. Inamoto T., Papineni S., Chintharlapalli S., Cho S.D., Safe S., Kamat A.M. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther 2008, 7(12):3825-3833.
44. Zeng H., Qin L., Zhao D., Tan X., Manseau E.J., Van Hoang M., et al. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J Exp Med 2006, 203(3):719-729.
45. Zhao D., Desai S., Zeng H. VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: role in VEGF-induced, angiogenesis. Int J Cancer 2011, 128(11):2602-2612.
46. Wu H.T., Lin S.H., Chen Y.H. Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetables. J Agric Food Chem 2005, 53(13):5164-5169.
47. Chang X., Tou J.C., Hong C., Kim H.A., Riby J.E., Firestone G.L., et al. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005, 26(4):771-778.
48. Yamada S., Bu X.-Y., Khankaldyyan V., Gonzales-Gomez I., McComb J.G., Laug W.E. Effect of the angiogenesis inhibitor cilengitide (Emd 121974) on glioblastoma growth in nude mice. Neurosurgery 2006, 59(6):1304-1312.
49. Riby J.E., Firestone G.L., Bjeldanes L.F. 3,3'-diindolylmethane reduces levels of HIF-1alpha and HIF-1 activity in hypoxic cultured human cancer cells. Biochem Pharmacol 2008, 75(9):1858-1867.
50. Mohan H.M., Aherne C.M., Rogers A.C., Baird A.W., Winter D.C., Murphy E.P. Molecular pathways: the role of NR4A orphan nuclear receptors in cancer. Clin Cancer Res 2012, 18(12):3223-3228.